Investment case
Seagen Inc.
SGEN · 6 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 6 macro, policy, and market developments to Seagen Inc. since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for SGEN yet, so no modelled value is shown. The SGEN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run SGEN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
Increased investor scrutiny on BTK inhibitor pipeline assets across the industry, potential re-evaluation of development risks.
· Moves probability of success for btk inhibitor pipeline assets, discount rate for r&d heavy companies
What changed, by assumption
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials
- 2026-09-29Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen
- 2026-09-09CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+
- 2026-09-01Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
- 2026-09-21Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen | watch | 1-5y | 0.20 |
| 2026-09-21 | Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets | watch | 1-3m | 0.10 |
| 2026-09-15 | BioMarin Pharmaceutical Inc. Discontinues VOXZOGO Development for Noonan Syndrome | watch | 3-12m | 0.10 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients Aged 2+ | watch | 1-3m | 0.20 |
| 2026-09-01 | Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials | watch | 1-3m | 0.30 |
| 2026-09-01 | Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026 | watch | 1-3m | 0.20 |